[Reversible autonomic dysfunction in a young woman with septic multiple organ dysfunction syndrome].
METHODS
A 24-year-old woman was admitted for treatment of a meningococcal infection accompanied by fulminant autonomic dysfunction.


METHODS
Laboratory tests indicated acute renal failure and disseminated intravascular coagulopathy (creatinine 183 mmol, D-dimer 1.52 mg/l). The initial central venous oxygen saturation was 60-65%. The diagnosis of severe septic shock was supported by a high procalcitonin level of 66.7 ng/ml, CRP of 79.8 mg/l, and a WBC count of 12.2 Gpt/l.


METHODS
Treatment of sepsis with antibiotics (ciprofloxacin, penicillin G, ceftriaxon and erythromycin in standard dosages), activated protein-C, hydrocortisone and GMA-embedded immunoglobulin led to complete cure and restoration of normal autonomic function.


CONCLUSIONS
This case shows that even in multiple organ dysfunction syndrome autonomic dysfunction can occur which is improved by adequate treatment.
Schmidt
H
H
Universitätsklinik und Poliklinik für Innere Medizin III. hendrik.schmidt@medizin.uni-halle.de
Flieger
R R
RR
Hennen
R
R
Tymiec
P
P
Winkler
M
M
Hoyer
D
D
Buerke
M
M
Müller-Werdan
U
U
Werdan
K
K
D000328:Adult; D000900:Anti-Bacterial Agents; D001145:Arrhythmias, Cardiac / Q000175:diagnosis / Q000503:physiopathology; D001342:Autonomic Nervous System Diseases / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D002628:Chemoreceptor Cells / Q000503:physiopathology; D003131:Combined Modality Therapy; D003422:Critical Care; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D007070:Immunoglobulin A / Q000627:therapeutic use; D007075:Immunoglobulin M / Q000627:therapeutic use; D008589:Meningococcal Infections / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D009102:Multiple Organ Failure / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D011486:Protein C / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012684:Sensory Thresholds / Q000502:physiology; D012772:Shock, Septic / Q000150:complications* / Q000503:physiopathology / Q000628:therapy
D000900:Anti-Bacterial Agents; D007070:Immunoglobulin A; D007075:Immunoglobulin M; D011486:Protein C; D011994:Recombinant Proteins; C060166:pentaglobulin; C421124:drotrecogin alfa activated